InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
IPO Year: 2019
Exchange: NASDAQ
Website: inmodemd.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 4/29/2025 | Buy → Neutral | BTIG Research | |
| 4/28/2025 | $22.00 → $16.00 | Outperform → Neutral | Robert W. Baird |
| 10/17/2024 | $25.00 | Buy | BTIG Research |
| 7/23/2024 | $21.00 → $19.00 | Buy → Hold | Jefferies |
| 11/3/2023 | $52.00 → $24.00 | Buy → Neutral | UBS |
| 10/13/2023 | $55.00 → $22.00 | Buy → Hold | Canaccord Genuity |
| 3/29/2023 | $40.00 | Buy | UBS |
| 2/17/2023 | Buy → Hold | Needham | |
| 12/21/2022 | $44.00 | Overweight | Barclays |
| 10/12/2022 | $40.00 | Buy | Jefferies |
In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: Quarterly GAAP revenues of $77.9 million, compared to $80.3 million in the first quarter of 2024.Quarterly revenues from consumables and service of $20.2 million, a decrease of 10% compared to the first quarter of 2024.GAAP operating income of $15.6 million, *non-GAAP operating income of $18.1 million.Total cash position of $512.9 million as
Conference call to be held on Monday, April 28, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 14, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter 2025 before the Nasdaq market opens on Monday, April 28, 2025. InMode is currently finalizing its financial results for the first quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I
YOKNEAM, Israel, March 26, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Moshe Mizrahy, Chief Executive Officer, and Yair Malca, Chief Financial Officer, will present at the 24th Annual Needham Virtual Healthcare Conference on April 8, 2025. The fireside chat, moderated by Michael Matson, Senior Equity Analyst, is scheduled for 2:15 pm Eastern Time on Tuesday, April 8, and a live webcast of the presentation can be accessed here. InMode will also hold one-on-one investor meetings that same day. To schedule a meeting, please contact your Needham representative. For more information about the event, visit InMo
Clarifies Capital Allocation Strategy and Commitment to Shareholder Returns Refutes Misconceptions on Staffing and Production Asserts No Justification for Additional Legal Action YOKNEAM, Israel, March 6, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated January 15, 2025. The letter can be viewed here The full text of the letter follows: March 6, 2025 Mr. Pedro EscuderoCEO and CIODOMA Perpetual Capital Management LLC Dear Mr. Escudero, As CEO of InMode, I felt it was
YOKNEAM, Israel, March 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences in March: Barclays 27th Annual Global Healthcare Conference Presenters: Yair Malca, Chief Financial Officer Format: In-person fireside chat moderated by Matt Miksic, Senior Equity Analyst, and one-on-one meetings Location: Miami, FL When: Wednesday, March 12 at 9:00 am EDT A live webcast of the presentation can be accessed here. Oppenheimer 34th Annual Healthcare MedTech & Services Conference Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer For
Quarterly GAAP revenues of $97.9 million and full year revenue of $394.8 million Returned $285.4 million of capital to shareholders in full year 2024 Together with new 10% program, represents repurchase of approximately 27% of shares outstanding within 15 month timeframe, with the potential of substantial additional capital return in 2025 YOKNEAM, Israel, Feb. 4, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year 2024. F
YOKNEAM, Israel, Feb. 3, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced that Yair Malca, Chief Financial Officer will host investor meetings at the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference in Snowbird, UT on Wednesday, February 12, 2025. Interested investors are welcome to contact their BTIG salesperson and schedule a meeting. For more information about the event, visit InMode's investor relations site here. About InMode InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF"
Conference call rescheduled to Tuesday, February 4, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 16, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it has adjusted the date for its fourth quarter and full year 2024 earnings conference call to an earlier date. Originally scheduled for Thursday, February 6, the call will now be held on Tuesday, February 4, 2025, at 8:30 am Eastern Standard Time. The company plans to release its financial results before the Nasdaq market opens that same day. InMode will host a conference call to discuss the fourth quarter and full year 2024 financial results
Believes the Board Must Immediately Execute a Tender Offer for 30% of the Company Lays Out Action Plan to Restore Investor Confidence, Including an additional 10% Share Buyback in 2025 Announces Intent to Fight for Shareholders Should InMode Not Take Appropriate Action MIAMI, Jan. 15, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode") today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to accelerate and increase its stock repurchase. The letter can be downloaded here T
Conference call to be held on Thursday, February 6, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 8, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year 2024 before the Nasdaq market opens on Thursday, February 6, 2025. InMode is currently finalizing its financial results for the fourth quarter and full year of 2024. Management believes that preliminary results reflect stronger-than-expected headwinds in the aesthetics industry, further intensified by broader macroeconomic challenges. While complete financial inform
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
SC 13G/A - InMode Ltd. (0001742692) (Subject)
BTIG Research downgraded InMode from Buy to Neutral
Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously
BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00
Jefferies downgraded InMode from Buy to Hold and set a new price target of $19.00 from $21.00 previously
UBS downgraded InMode from Buy to Neutral and set a new price target of $24.00 from $52.00 previously
Canaccord Genuity downgraded InMode from Buy to Hold and set a new price target of $22.00 from $55.00 previously
UBS initiated coverage of InMode with a rating of Buy and set a new price target of $40.00
Needham downgraded InMode from Buy to Hold
Barclays initiated coverage of InMode with a rating of Overweight and set a new price target of $44.00
Jefferies initiated coverage of InMode with a rating of Buy and set a new price target of $40.00
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K/A - InMode Ltd. (0001742692) (Filer)
S-8 - InMode Ltd. (0001742692) (Filer)
20-F - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
SCHEDULE 13D - InMode Ltd. (0001742692) (Subject)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
6-K - InMode Ltd. (0001742692) (Filer)
In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: Quarterly GAAP revenues of $77.9 million, compared to $80.3 million in the first quarter of 2024.Quarterly revenues from consumables and service of $20.2 million, a decrease of 10% compared to the first quarter of 2024.GAAP operating income of $15.6 million, *non-GAAP operating income of $18.1 million.Total cash position of $512.9 million as
Conference call to be held on Monday, April 28, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 14, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter 2025 before the Nasdaq market opens on Monday, April 28, 2025. InMode is currently finalizing its financial results for the first quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I
Clarifies Capital Allocation Strategy and Commitment to Shareholder Returns Refutes Misconceptions on Staffing and Production Asserts No Justification for Additional Legal Action YOKNEAM, Israel, March 6, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today sent a letter to DOMA Perpetual Capital Management LLC ("DOMA") CEO and CIO Pedro Escudero in response to issues presented in his public letter dated January 15, 2025. The letter can be viewed here The full text of the letter follows: March 6, 2025 Mr. Pedro EscuderoCEO and CIODOMA Perpetual Capital Management LLC Dear Mr. Escudero, As CEO of InMode, I felt it was
Quarterly GAAP revenues of $97.9 million and full year revenue of $394.8 million Returned $285.4 million of capital to shareholders in full year 2024 Together with new 10% program, represents repurchase of approximately 27% of shares outstanding within 15 month timeframe, with the potential of substantial additional capital return in 2025 YOKNEAM, Israel, Feb. 4, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the fourth quarter and full year 2024. F
Conference call rescheduled to Tuesday, February 4, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 16, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it has adjusted the date for its fourth quarter and full year 2024 earnings conference call to an earlier date. Originally scheduled for Thursday, February 6, the call will now be held on Tuesday, February 4, 2025, at 8:30 am Eastern Standard Time. The company plans to release its financial results before the Nasdaq market opens that same day. InMode will host a conference call to discuss the fourth quarter and full year 2024 financial results
Believes the Board Must Immediately Execute a Tender Offer for 30% of the Company Lays Out Action Plan to Restore Investor Confidence, Including an additional 10% Share Buyback in 2025 Announces Intent to Fight for Shareholders Should InMode Not Take Appropriate Action MIAMI, Jan. 15, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode") today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to accelerate and increase its stock repurchase. The letter can be downloaded here T
Conference call to be held on Thursday, February 6, 2025, at 8:30 a.m. Eastern Standard Time YOKNEAM, Israel, Jan. 8, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the fourth quarter and full year 2024 before the Nasdaq market opens on Thursday, February 6, 2025. InMode is currently finalizing its financial results for the fourth quarter and full year of 2024. Management believes that preliminary results reflect stronger-than-expected headwinds in the aesthetics industry, further intensified by broader macroeconomic challenges. While complete financial inform
YOKNEAM, Israel, Oct. 30, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Highlights: Quarterly GAAP revenue of $130.2 million (which consists of $98.3 million of net sales in Q3 and $31.9 million of pre-orders from the first half of 2024).Quarterly revenues from consumables and service of $15.8 million, a decrease of 11% compared to the third quarter of 2023.GAAP operation income of $48.2 million, *non-GAAP operation income of $52.2 million.Total cash position of $684.9 million as of September 30, 2024
Expects Q3 Revenue Between $130.0 Million -$130.1 Million (including $31.9 Million in Revenue from First Half of 2024 Pre-orders), Decreases Full Year 2024 Guidance to $410 Million-$420 Million Conference call to be held on Wednesday, October 30, 2024, at 8:30 a.m. Eastern Time YOKNEAM, Israel, Oct. 10, 2024 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the third quarter of 2024 before the Nasdaq market opens on Wednesday, October 30, 2024. InMode is
YOKNEAM, Israel, Aug. 1, 2024 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Highlights: Quarterly GAAP revenue of $86.4 million, a decrease of 36.5% compared to the second quarter of 2023. InMode's proprietary surgical technology platforms engaged in minimally invasive and subdermal ablative treatments represented 87% of its quarterly revenues, while 6% were derived from InMode's traditional laser and non-invasive RF platforms and 7% were derived from InMode's hands-free platforms. Pro-forma revenue (includin